成大生物
(688739)
| 流通市值：82.90亿 | | | 总市值：83.87亿 |
| 流通股本：4.12亿 | | | 总股本：4.16亿 |
| 报告期 | 2026-06-30 | 2026-03-31 | 2025-12-31 | 2025-09-30 |
| 公司类型 | 通用 | 通用 | 通用 | 通用 |
| 一、营业总收入 | 677,265,772.37 | 273,347,755.58 | 1,390,287,449 | 1,095,886,627.32 |
| 营业收入 | 677,265,772.37 | 273,347,755.58 | 1,390,287,449 | 1,095,886,627.32 |
| 二、营业总成本 | 591,653,690.31 | 269,281,252.62 | 1,175,494,522.57 | 863,198,199.48 |
| 营业成本 | 174,451,795.97 | 70,942,904.08 | 286,816,833.67 | 223,229,149.15 |
| 税金及附加 | 15,717,243.87 | 7,187,027.26 | 20,746,015.34 | 15,713,899 |
| 销售费用 | 172,007,055.62 | 73,321,825.63 | 379,937,530.34 | 281,093,120.33 |
| 管理费用 | 128,931,048.08 | 68,792,649.69 | 229,444,605.06 | 161,475,353.51 |
| 研发费用 | 105,295,709.12 | 52,216,129.78 | 294,037,224.46 | 210,301,914.79 |
| 财务费用 | -4,749,162.35 | -3,179,283.82 | -35,487,686.3 | -28,615,237.3 |
| 其中:利息费用 | 210,834.42 | 109,816.8 | 1,426,723.44 | 473,264.2 |
| 其中:利息收入 | 7,322,515.48 | 4,913,229.63 | 37,180,355.54 | 28,670,794 |
| 三、其他经营收益 | | | | |
| 加:公允价值变动收益 | -17,834,271.66 | -1,525,282.2 | 63,167,530.34 | -1,440,207.42 |
| 加:投资收益 | 18,408,026.09 | 7,422,920.54 | 15,934,307.61 | 20,375,495.23 |
| 资产处置收益 | - | - | -601.76 | -601.76 |
| 资产减值损失(新) | -28,097,762.42 | -5,789,976.03 | -132,085,345.56 | -34,026,310.37 |
| 信用减值损失(新) | -10,701,188.11 | -6,760,818.27 | -8,443,874.61 | -17,464,546.37 |
| 其他收益 | 7,781,968.55 | 3,900,867.45 | 17,674,589.34 | 12,024,463.89 |
| 四、营业利润 | 55,168,854.51 | 1,314,214.45 | 171,039,531.79 | 212,156,721.04 |
| 加:营业外收入 | 22,846.02 | 7,933.63 | 302,287.84 | 188,074.34 |
| 减:营业外支出 | 241,206.68 | 89,983.81 | 1,737,275.33 | 1,197,325.69 |
| 五、利润总额 | 54,950,493.85 | 1,232,164.27 | 169,604,544.3 | 211,147,469.69 |
| 减:所得税费用 | 21,669,933.98 | 3,139,876.42 | 37,814,214.9 | 46,335,452.14 |
| 六、净利润 | 33,280,559.87 | -1,907,712.15 | 131,790,329.4 | 164,812,017.55 |
| (一)按经营持续性分类 | | | | |
| 持续经营净利润 | 33,280,559.87 | -1,907,712.15 | 131,790,329.4 | 164,812,017.55 |
| (二)按所有权归属分类 | | | | |
| 归属于母公司股东的净利润 | 33,280,571.89 | -1,907,712.15 | 131,790,329.4 | 164,812,017.55 |
| 少数股东损益 | -12.02 | - | - | - |
| 扣除非经常损益后的净利润 | 26,833,385.1 | -10,365,108.1 | 40,173,358.75 | 134,864,740.7 |
| 七、每股收益 | | | | |
| (一)基本每股收益 | 0.08 | -0.01 | 0.32 | 0.4 |
| (二)稀释每股收益 | 0.08 | -0.01 | 0.32 | 0.4 |
| 九、综合收益总额 | 33,280,559.87 | -1,907,712.15 | 131,790,329.4 | 164,812,017.55 |
| 归属于母公司股东的综合收益总额 | 33,280,571.89 | -1,907,712.15 | 131,790,329.4 | 164,812,017.55 |
| 归属于少数股东的综合收益总额 | -12.02 | - | - | - |
| 公告日期 | 2026-08-25 | 2026-04-29 | 2026-04-21 | 2025-10-30 |
| 审计意见(境内) | | | 标准无保留意见 | |